The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

Where could be the top place to invest this spring? Europe. That's according to the latest edition of the hugely influential ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

Valeo Financial Advisors LLC decreased its holdings in Sanofi (NASDAQ:SNY – Free Report) by 62.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund ...

The Sensex closed 58 points higher at 75,997, while the Nifty gained 30 points to settle at 22,960. The rally was primarily ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

JPMorgan raised the firm’s price target on Sanofi (SNY) to EUR 110 from EUR 105 and keeps a Neutral rating on the shares.Maximize Your ...

Sanofi's SNY -1.06% + Free Alerts short percent of float has fallen 8.33% since its last report. The company recently ...